With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > BUSINESS
BUSINESS
- Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
- Higher Rate of Resistance to Xofluza Seen in Younger Children: Shionogi
September 3, 2019
- Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology
September 3, 2019
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- Kowa Gears Up for Glanatec PII Trial in US
September 3, 2019
- Japan Approves Zykadia’s Smaller Film-Coated Tablets
September 3, 2019
- AstraZeneca, Osaka Govt Join Forces on Anti-Allergy Measures
September 3, 2019
- Digital Technologies Hold Key for Japan’s Participation in Global Studies: IQVIA R&D Solutions Head
September 3, 2019
- Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values
September 2, 2019
- Daiichi Sankyo’s Pain Drug Tarlige Sweeps Promotion Rankings in June: Impact Track
September 2, 2019
- Kadcyla Filed in Japan for Adjuvant Use in Early Breast Cancer
September 2, 2019
- Osaka Startup Looks to Reposition Polaprezinc/Selenium Combination as NASH Treatment
August 30, 2019
- Xofluza Approved in Taiwan: Shionogi
August 30, 2019
- Hisamitsu Seeks Label Expansion for Fentos Tape
August 30, 2019
- 3 Japan Drug Makers Plow US$65 Million into VC Fund
August 30, 2019
- Eisai to Develop Aussie Firm’s Digital Cognitive Function Self-Assessment Tool in Japan
August 29, 2019
- Nippon Kayaku Skips September Listing for Lilly’s Portrazza
August 29, 2019
- Ono Files BTK inhibitor Tirabrutinib in Japan for Primary CNS Lymphoma
August 29, 2019
- Kyowa Kirin Finally Bags US OK for Parkinson’s Disease Istradefylline
August 29, 2019
- Mitsubishi Tanabe Launches US PIII Study of Continuous SC Liquid Levodopa/Carbidopa for Parkinson’s Disease
August 29, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…